Eigenlayer Airdrop: Most Disappointing Airdrop SO FAR?!
- 83
Eigenlayer just announced its EIGEN token launch and season 1 Stakedrop, and Crypto Twitter is not liking the way the ...
Boxmining
Stay ahead of the crypto game with Boxmining! From the latest news to insider trends, we’ve got you covered in the fast-paced world of cryptocurrencies. SUBSCRIBE and WIN!
These videos are for information purposes only and do not constitute financial advice. These videos are not intended for people in jurisdictions where their contents would breach local laws or regulations You are responsible for following any restrictions and/or requirements for any token holdings/sales/offerings/airdrops, as well as cryptocurrency exchanges/platforms. Boxmining and/or its employees may hold the cryptocurrencies mentioned in these videos.
Contact me ONLY via the email below! Beware of scammers that use different emails.
Email: [email protected]
Telegram handle: @boxmining
Instagram: https://www.instagram.com/boxmining/
Facebook: https://www.facebook.com/MichaelGuBoxmining
Twitter: https://twitter.com/boxmining
I will NEVER contact you privately with any offers. Please report these scammers.
Lastest news
- Prospera Energy Inc. Announces 2023 Financial Results
- WATCH by Aisles: A Revolutionary AI System for Public Safety
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)